Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06038474 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Descartes-08 for Patients With Systemic Lupus Erythematosus

Study acronym: SLE-001
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary completion date: Dec 1, 2025 to Dec 1, 2026 Completion date: Nov 1, 2026 to Dec 1, 2027v6 Show 1 more changeShow less
    • Completion date: Nov 1, 2026 to Dec 1, 2027
  2. Trial status: Recruiting to Active, Not Recruiting Enrollment target: estimated 30 to confirmed 6 · Primary completion date: Nov 1, 2025 to Dec 1, 2025 · Site details revisedv5 Show 3 more changesShow less
    • Enrollment target: estimated 30 to confirmed 6
    • Primary completion date: Nov 1, 2025 to Dec 1, 2025
    • Site details revised
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruitingv3
  5. Start date: Nov 1, 2023 to Feb 12, 2024 Secondary endpoints revised (4)v2 Show 1 more changeShow less
    • Secondary endpoints revised (4)

    See this version in full on ClinicalTrials.gov ↗

  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase II study to evaluate the safety, tolerability and manufacturing feasibility of Descartes-08 CAR T-cells in patients with Systematic Lupus erythematosus (SLE).
Trial Details
NCT Number NCT06038474
Lead Sponsor Cartesian Therapeutics
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 6 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov